Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Key facts

Where
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin, Wenzhou, Wuhan, and Xi'an, ChinaSee the 17 sites
Phase
Phase 3

Where in China

  • Beijing Pinggu District HospitalBeijing, ChinaContact: yufeng li (principal investigator)Taking people
  • Peking University Third HospitalBeijing, ChinaContact: Dan Zhu (principal investigator)Taking people
  • Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaContact: Lianrui Guo (principal investigator)Taking people
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Limin Tian (principal investigator)Taking people
  • Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Jiyan Chen (principal investigator)Taking people
  • Heilongjiang Provincial HospitalHarbin, ChinaContact: weimin wang (principal investigator)Taking people
  • The Fourth Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaContact: ZhiFeng Cheng (principal investigator)Taking people
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaContact: Hongwei Jiang (principal investigator)Taking people
  • Jiangsu Province HospitalNanjing, ChinaContact: Xiwei Zhang (principal investigator)Taking people
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)Taking people
  • Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Xinwu Lu (principal investigator)Taking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Weiguo Fu (principal investigator)Taking people
  • Tianjin Medical University General HospitalTianjin, ChinaContact: Xiangchen Dai (principal investigator)Taking people
  • Tianjin People's HospitalTianjin, ChinaContact: Li Li (principal investigator)Taking people
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Jingyong Huang (principal investigator)Taking people
  • Wuhan University Medical College - Hubei Zhongshan HospitalWuhan, ChinaContact: Jingyi Zhang (principal investigator)Taking people
  • The First Affiliated Hospital of Xi'an Medical UniversityXi'an, ChinaContact: Ya Li (principal investigator)Taking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07223593EU 2025-523283-21-00
Record updated
4 November 2026
Original description
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.Read full original descriptionShow less

A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial

The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.

Inclusion: Have symptomatic PAD with intermittent claudication of Fontaine Stage II; Have an Ankle Brachial Index (ABI) of 0.9 or less.

Exclusion: Have a planned lower limb surgery or any other surgery affecting walking ability; Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial; Had stroke, transient ischemic attack, myocardial infarction, coronary or carotid revascularization, or hospitalization for unstable angina pectoris within 60 days prior to screening; Have walking ability limited by conditions other than PAD; Have heart failure presently classified as being in New York Heart Association class III - IV; Have Hemoglobin A1c (HbA1c) greater than 10%; Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2).

ClinicalTrials.gov NCT07223593 · EU CTIS 2025-523283-21-00